US pharmaceutical company Viatris has announced plans to wind down and close its manufacturing plant in Damastown in west Dublin, which employs around 340 people.
The company said there will be no immediate job losses but that the wind down of production activities will start in the first half of 2028, and will be completed by the end of 2028.
"We will be consulting with employee representatives on a plan for the reduction of staff to whom we intend to offer comprehensive redundancy packages," said David Delaney, Head of Policy and Health and Value.
Staff at the site were informed at a meeting this morning.
RTÉ News understands there may be redeployment opportunities within the company as it is hiring for open positions at its other sites in Ireland.
The Damastown site manufactures generic medicines and RTÉ News understands that the decision to wind down the operation is linked to the impact of rising costs.
Viatris has manufacturing and R&D facilities in Dublin and Galway, as well as a Dublin-based development, commercial and operations hub.
The company has a workforce of more than 1,000 across these sites.
Viatris said the decision to close the Damastown plant follows the completion of an enterprise-wide strategic review which showed declining demand in parts of its global portfolio and more capacity across the entire network than required.
"This news in no way reflects upon the company's genuine appreciation for the commitment and work ethic of colleagues in Ireland," Viatris said in a statement.
"Throughout this process, we remain focused on meeting our current customer commitments to ensure an uninterrupted supply of medicines for patients," it said.
"There are approximately 340 employees at the site, and we are committed to treating all employees fairly and with respect," the company added.
Viatris said it remains committed to doing business in Ireland and serving patients behind an extensive portfolio of products across a broad range of therapeutic areas.
"The organisation prides itself on delivering significant value to Health Service Executive (HSE)," the company said.
In 2024, Viatris announced plans to wind down and close its manufacturing plant in Little Island in Cork by 2028.
The facility employs around 200 people.
In 2020, Viatris announced the closure of a plant in Baldoyle in Dublin with the loss of 440 jobs.
A year later a further 70 roles were cut from its Irish corporate head office following a global restructuring of operations.
Viatris was formed in 2020 from a merger between Mylan and Upjohn, which was spun-out of Pfizer.
